Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEAL: Neoadjuvant T-DM1 + Lapatinib in HER2+ Breast Cancer
NCT02073487Phase 2Completed
- Sponsor
- Houston Methodist Research Institute
- Start
- Feb 2014
- Primary completion
- Jan 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab emtansine, lapatinib in breast cancer, sponsored by Houston Methodist Research Institute. Started Feb 2014; status: completed.
02
Drugs
trastuzumab emtansinelapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02073487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02073487.